metformin has been researched along with Ewing Sarcoma in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin has long been an attractive therapeutic option for EwS, but hypoxia limits its efficacy." | 5.56 | Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways. ( Cheng, H; Lau, CC; Nan, X; Qiu, B; Sheng, J; Wang, J; Wong, STC; Yin, Z; Yustein, JT; Zhao, H, 2020) |
| "Metformin shows preclinical anti-cancer activity through multiple pathways." | 3.30 | A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. ( Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA, 2023) |
| "Metformin has long been an attractive therapeutic option for EwS, but hypoxia limits its efficacy." | 1.56 | Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways. ( Cheng, H; Lau, CC; Nan, X; Qiu, B; Sheng, J; Wang, J; Wong, STC; Yin, Z; Yustein, JT; Zhao, H, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Metts, JL | 1 |
| Trucco, M | 1 |
| Weiser, DA | 1 |
| Thompson, P | 1 |
| Sandler, E | 1 |
| Smith, T | 1 |
| Crimella, J | 1 |
| Sansil, S | 1 |
| Thapa, R | 1 |
| Fridley, BL | 1 |
| Llosa, N | 1 |
| Badgett, T | 1 |
| Gorlick, R | 1 |
| Reed, D | 1 |
| Gill, J | 1 |
| Nan, X | 1 |
| Wang, J | 1 |
| Cheng, H | 1 |
| Yin, Z | 1 |
| Sheng, J | 1 |
| Qiu, B | 1 |
| Lau, CC | 1 |
| Yustein, JT | 1 |
| Zhao, H | 1 |
| Wong, STC | 1 |
| Garofalo, C | 1 |
| Capristo, M | 1 |
| Manara, MC | 1 |
| Mancarella, C | 1 |
| Landuzzi, L | 1 |
| Belfiore, A | 1 |
| Lollini, PL | 1 |
| Picci, P | 1 |
| Scotlandi, K | 1 |
1 trial available for metformin and Ewing Sarcoma
| Article | Year |
|---|---|
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neo | 2023 |
2 other studies available for metformin and Ewing Sarcoma
| Article | Year |
|---|---|
Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms | 2020 |
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2013 |